Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374584 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7271175 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7262810 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7268989 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7196612 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL8375073 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7194399 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7270390 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7262770 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA | |
| SCHEMBL7263369 | 0.87 | TRPV1 (0.71) | TRPV1HPGDCA1CA2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1360172-A1 | PPAR AGONISTS | Pfizer Products Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002064549-A1 | PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | PPARA, PPARG, PPARD | TRPV1 2849/4885HPGD 399/4885CA1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.